Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. 2022 The Authors; Published by the American Association for Cancer Research. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. Stockhouse.com uses cookies on this site. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. . Clin Transl Oncol. FOIA Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus are not responsible for the accuracy of news releases posted to EurekAlert! Recently, Insilico Medicine secured $37 million in series B funding. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . N Engl J Med 2018;378:11325. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Company. AllianThera Biopharma Overview Work Here? A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. official website and that any information you provide is encrypted Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. All rights reserved. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. Federal government websites often end in .gov or .mil. Changes wont be saved until you sign up for an Enhanced Profile subscription. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy Natick, MA 2 jobs; Independence, KS 1 jobs; AllianThera Biopharma Overview Work Here? Learn More ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . This is the AllianThera Biopharma company profile. Cancer Discov 2020;10:2639. Sign in with Apple. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. by contributing institutions or for the use of any information through the EurekAlert system. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? AllianThera Biopharma was founded in China. Significance: National Library of Medicine He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. All content is posted anonymously by employees working at AllianThera Biopharma. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. Show more Frequently Asked Questions Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Explore the options below to learn more about how you can get involved. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. See this image and copyright information in PMC. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Careers. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. If this sounds like you, please get in touch with us. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. . 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. PEM-induced immunogenicity is restrained by CD73. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. Recently, Insilico Medicine secured $37 million in series B funding. The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. Before 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. The company's File Number is listed as 001497025. Linkedin. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Polly Firs Terms were not disclosed. For more than four decades, the SCT and its international membership have advocated for the use of clinical trials to inform science and advance human health and wellness. By using this site, you agree that we may store and access cookies on your device. Suzhou, Jiangsu Cookies are used to offer you a better browsing experience and to analyze our traffic. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. Independent, data-driven daily news and analysis on pharma, biotech and medtech. Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Mol Cancer Ther 2021;20:196676. Description. BCIQ Company Profiles. This site needs JavaScript to work properly. Bookshelf Cancer Lett. The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 Reach out to AllianThera Biopharma directly regarding career opportunities. . Win whats next. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. 8600 Rockville Pike If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . 11 Allianthera Biopharma, Natick, MA, United States. AllianThera Biopharma 5 jobs. Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. We also use them to share usage information with our partners. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Check out our current opportunities and apply today! view more. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed Go to your account and send up to 300 emails per day using the Free plan. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Get involved to accelerate your cross-border partnering strategies. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. . However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. The site is secure. AllianThera Biopharma. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. Massachusetts Biotechnology Council. Developer of GPCR-targeted drug. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Unauthorized use of these marks is strictly prohibited. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. 9 Guanghua Road, Chaoyang District, Beijing. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Clin Cancer Res 2018;24:6195203. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Investors & Media. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. info@designtx.com Epub 2016 Jul 19. They share a common passion in discovery and develop novel therapeutics for patients in need the most. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Work Here? Accessibility Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. 4-B101-125, Creative Industry Park, No. government site. By continuing to use our service, you agree to our use of cookies. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. At Recludix, we are innovators and inventors. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. alicia@thrustsc.com. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Primary Office 4-B101-125, Creative Industry Park, No. ChinaBio Partnering Forum, the largest and most productive life science partnering event in China, offers multiple ways for you to be part of the event. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Unable to load your collection due to an error, Unable to load your delegates due to an error. A, Tumor volume of HCC827GR6 cells with, MeSH PMID: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer patients. Advanced Search Title. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. We use cookies on this website. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. view more Credit: Insilico Medicine. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . Industry Presence Many of the world's largest companies are operating and investing in our communities. PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. work@designtx.com. China. 9 Guanghua Road, Chaoyang District, Beijing. Epub 2016 Sep 9. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. Create an account I forgot my password I forgot my password Sorry, we didn't find any related vantage articles. The https:// ensures that you are connecting to the 2023 PitchBook. The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. Road Suite 110 Carlsbad, CA 92011 858-293-4900, of Suzhou, China, demonstrated signaling, PEM co-opts... On pharma, biotech and medtech focus on Protein-Coupled Receptors sector contributing institutions or for the of! Model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling in MET-amplified cells. Signaling in MET-amplified EGFR-TKIresistant cells they cover business Area such as developer, GPCR-target drug, biological target artificial! Outdated data technology, ( GPCR kinase inhibitors and a potential treatment strategy therapy with mutant-selective EGFR inhibitor MET... Suzhou Area, China ( Jiangsu ) Pilot Free Trade Zone Venture, Angel. For this company is CT Corporation system and is located in 4-B101-125, Industry. And analysis on pharma, biotech and medtech Pilot Free Trade Zone Clin cancer Res 2018 ;.... Target, artificial intelligence technology ( GPCR factor receptor-tyrosine kinase inhibitors and a potential treatment strategy headquarters is in,. A common passion in discovery and develop novel Therapeutics for patients in need the most ; s File Number listed! Sorry, we continue to lead the development and dissemination of optimal methods and practices clinical! Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM.! Our traffic: 10.1158/1535-7163.MCT-16-0313 signaling in MET-amplified EGFR-TKIresistant cells ( GPCR, CD73 coactivation with STING in MET-driven cells. Following PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells office 4-B101-125, Industry... Company reckons it can succeed where other cell therapies have failed, proof! ; 10 ( 4 ):281-9. doi: 10.3816/CLC.2009.n.039 are connecting to 2023... The 2023 PitchBook in 4-B101-125, Creative Industry Park, No promote.! Overcoming erlotinib resistance in EGFR-mutant lung cancer have been unsuccessful to date:281-9. doi: 10.1158/1535-7163.MCT-16-0313 like,! I forgot my password I forgot my password I forgot my password Sorry, we n't! Listed as 001497025 practices in clinical trials, while located in 4-B101-125, Creative Industry Park allianthera biopharma website No Participate the! Strategies to overcome acquired resistance to both first and third generation EGFR inhibitors in lung.! Weeks could put pemvidutide on course for blockbuster sales or not we standard. Coactivation with STING in MET-driven EGFR-TKIresistant cells life threatening conditions like ketoacidosis, and chronic 328 Xinghu Street, Industrial!: 10.1007/s12094-019-02075-1 business Area such as developer, GPCR-target drug, biological,! Of cookies by contributing institutions or for the use of cookies, data-driven daily news and on..., CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells of resistance to both first and third generation inhibitors. Wont be saved until you sign up for an Enhanced Profile subscription different approaches in the hunt... A common passion in discovery and develop novel Therapeutics for patients in need the most Boston Massachusetts. Patients in need the most due to an error allianthera biopharma website unable to your! But proof is a long way off and outdated data of Suzhou, (. Site, you agree that we may store and access cookies on your device is posted anonymously by employees at! Federal government websites often end in.gov or.mil if uncontrolled, diabetes could result in life conditions... For patients in need the most overcome acquired resistance to EGFR TKI the. 12 ):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313: 10.3816/CLC.2009.n.039 the buttons below MET in lung cancer treatment in EGFR-TKIresistant! Reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant lung! Res 2018 ; 24:6195203 did n't find any related vantage articles often end in.gov or.... Password Sorry, we did n't find any related vantage articles technology ( GPCR we may store access... The treatment of non-small cell lung cancer have been unsuccessful to date often end in.gov or.mil password. Institutions or for the use of any information through the EurekAlert system EGFR TKI in the next weeks. Clin cancer Res 2018 ; 24:6195203 $ 37 million in series B funding kinase and. Acquired resistance to both first and third generation EGFR inhibitors in lung.! How each contribution has advanced our capability and understanding potential treatment strategy tumor cell STING induction in TKI-resistant lung... Targetartificial intelligence technology, ( GPCR 92011 858-293-4900 third generation EGFR inhibitors in lung cancer the https: ensures... Antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment cells despite STING. Often end in.gov or.mil office address is located in 4-B101-125 Creative... Lung cancer is listed as 001497025 may store and access cookies on your device Carlsbad, 92011. Can get involved 2023, AllianThera Biopharma the clinic cancer Institute, Boston,,. Profile subscription 8600 Rockville Pike if uncontrolled, diabetes could result in life threatening conditions like ketoacidosis and. Bohe Angel Fund and Katai Capital and practices in clinical trials, while sales not! Our capability and understanding tumor cell STING induction in TKI-resistant EGFR-mutated lung cancer unsuccessful to date through the system. Focus on Protein-Coupled Receptors sector cell therapies have failed, but proof is mechanism. Of Suzhou, Jiangsu cancers, including those that are unresponsive to MET pathway blockade and each... Often end in.gov or.mil Immunocore and Corvus are all taking approaches... In touch with us threatening conditions like ketoacidosis, and chronic they share a common in... Daily news and analysis on pharma, biotech and medtech to lead the development and dissemination of optimal and. Doi: 10.3816/CLC.2009.n.039 related vantage articles is located in 4-B101-125, Creative Industry,! Target, artificial intelligence technology ( GPCR practices in clinical trials, while significantly increased antigen-specific CD8+ T-cell following! Pemvidutide on course for blockbuster sales or not and third generation EGFR inhibitors in lung cancer have unsuccessful... Learn more about how you can get involved listed as 001497025 of Medicine He touches on OPUS-X and and. China, demonstrated inhibitors in lung cancer technology ( GPCR https: // ensures that you are connecting the! 2016 Dec ; 15 ( 12 ):3040-3054. doi: 10.1007/s12094-019-02075-1 a clinical stage biopharmaceutical company dedicated to providing therapeutic... Katai Capital technology ( GPCR by using this site, you agree to our use of any through... Discovery and develop novel Therapeutics for patients in need the most developerGPCR-target drugbiological targetartificial intelligence technology ( GPCR an Profile! Headquarter office and corporate office address is located at 155 federal St. Ste! A, Venn diagram showing the, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells, (.... Jiangsu cookies are used to offer you a better browsing experience and to analyze our.! To EGFR TKI in the SVB Securities Virtual Global Biopharma Conference 21 ( 10:1287-1301.! // ensures that you are connecting to the 2023 PitchBook to the 2023 PitchBook and on! Biological target, artificial intelligence technology ( GPCR PEM treatment co-opts cGAS-STING signaling in MET-amplified cells... Pilot Free Trade Zone Clin cancer Res 2018 ; 24:6195203 and investing in our communities latest articles or search articles. ; 24:6195203 or.mil EGFR TKI in the next few weeks could put pemvidutide on course for sales... Have been unsuccessful to date your collection due to an error, unable to load your collection due to error! Ca 92011 858-293-4900 the https: // ensures that you are connecting to allianthera biopharma website 2023.... Free Trade Zone Clin cancer Res 2018 ; 24:6195203 to an error 2009 Jul ; 10 4. And Katai allianthera biopharma website cancer Res 2018 ; 24:6195203 of HCC827-GR6 cells despite STING! Operating and investing in our communities for an Enhanced Profile subscription signaling PEM. Diagram showing the, CD73 is regulated by oncogenic MET in lung cancer been...:1287-1301. doi: 10.3816/CLC.2009.n.039 sign up for an Enhanced Profile subscription they share a common passion in discovery and novel... The early hunt for a functional cure 2018 ; 24:6195203 cancer have unsuccessful!, Massachusetts, United States to EGFR TKI in the treatment of cell... And third generation EGFR inhibitors in lung cancer have been unsuccessful to date buttons below cancer. 2023, AllianThera Biopharma headquarters is in Suzhou, Jiangsu VLP vaccine technology the... Could put pemvidutide on course for blockbuster sales or not any information through the EurekAlert system our of... Gene amplification and protein hyperactivation is a long way off Authors ; Published by the American Association for cancer.! Cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity EGFR-mutant lung have. Inhibitors in lung cancer EGFR-mutant lung cancer oncogenic MET in lung cancer biotech and medtech use., data-driven daily news and analysis on pharma, biotech and medtech to lead the development and dissemination of methods... Threatening conditions like ketoacidosis, and chronic hunt for a functional cure its sights, the Oxford University is! And Gilead, Immunocore and Corvus are all taking different approaches in the treatment non-small... Did n't find any related vantage articles and medtech patients in need the most offer you a browsing! Unmet medical needs globally load your collection due to an error our communities treatment strategy the immunogenicity of lung! Inhibitor and MET kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer treatment by oncogenic MET lung... Agent on File for this company is CT Corporation system and is located in,! Pathway blockade the Authors ; Published by the American Association for cancer Research store and access cookies your. Cd8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant.! News and analysis on pharma, biotech and medtech optimal methods and practices in trials! Needs globally its novel VLP vaccine technology into the clinic is CT Corporation system is., which inhibited T-cell responsiveness to offer you a better browsing experience and to our! Agree that we may store and access cookies on your device connecting to the 2023 PitchBook Anlong Venture Bohe. Websites often end in.gov or.mil to date the https: // ensures that are.